这家总部位于新泽西州帕拉穆斯的公司成立于2017年，计划在纳斯达克上市，股票代码为STA。此次交 易的唯一承销商是Revere Securities。 Starton Holdings是一家处于临床试验二期阶段的生物技术公司，它正在利用连续交付技术对已获美国食 品药品监督管理局批准的癌症治疗用活性成分进行改进，采用的是美国食品药品监督管理局的505(b)(2) 监管途径。该公司专注于血液系统恶性肿瘤领域，其主打项目"STAR-LLD"旨在针对多发性骨髓瘤和慢 性淋巴细胞白血病。STAR-LLD的目标是开发lenalidomide的皮下和口服控释制剂(仿制Revlimid)，以提 高治疗效果。该公司还在探索将STAR-LLD与CAR-T疗法相结合的可能性，并拓展到其他癌症类型，包 括B细胞淋巴瘤和实体瘤。 Starton Holdings(STA.US)于上周四向美国证券交易委员会提交申请，计划通过首次公开募股筹集至多 4000万美元。该公司是一家专注于开发已获批准的抗癌药物缓释制剂的公司。该公司计划通过发行670 万股股票来筹集4000万美元，发行价区间为5美元至7美元。按照提议价格区间的中点计算，完全稀释市 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：600252 证券简称：中恒集团 公告编号：临2025-94 一、药品基本情况 1.药品名称：纳米炭铁混悬注射液 2.申请人：四川瀛瑞医药科技有限公司 3.适应症：实体瘤 4.注册分类：化学药品2类 5.受理号：CXHL2501026 广西梧州中恒集团股份有限公司 关于控股孙公司获得药物临床试验批准通知书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 近日，广西梧州中恒集团股份有限公司（以下简称"公司"或"中恒集团"）控股子公司重庆莱美药业股份 有限公司（以下简称"莱美药业"）之子公司四川瀛瑞医药科技有限公司（以下简称"瀛瑞医药"）自主研 发的创新抗癌药物"纳米炭铁混悬注射液"（以下简称"纳米炭铁"）获国家药品监督管理局签发《药物临 床试验批准通知书》，同意纳米炭铁联合标准放疗在实体瘤患者中开展临床试验。现将相关情况公告如 下： 6.通知书编号：2025LP03253 7.审批结论：纳米炭铁混悬注射液符合药品注册的有关要求，同意本品联合标准放疗在实体瘤患者中开 ...

南财智讯12月4日电，中恒集团公告，中恒集团收到国家药品监督管理局签发的《药物临床试验批准通 知书》，同意控股孙公司四川瀛瑞医药科技有限公司自主研发的创新抗癌药物"纳米炭铁混悬注射液"联 合标准放疗在实体瘤患者中开展临床试验。该药物以Fe²⁺作为抗癌有效成分，纳米炭作为载体，通过调 控铁死亡通路发挥抗癌作用，拟用于实体瘤治疗。目前，纳米炭铁二期临床试验进展顺利，已完成部分 入组试验，尚未有同类产品上市或处于在研末期。截至公告日，瀛瑞医药对该药物的累计研发投入为 9,428.26万元人民币（未经审计）。 ...

每经AI快讯，12月4日，莱美药业(300006.SZ)公告称，公司控股子公司瀛瑞医药自主研发的创新抗癌药 物"纳米炭铁混悬注射液"获国家药品监督管理局签发《药物临床试验批准通知书》，同意纳米炭铁联合 标准放疗在实体瘤患者中开展临床试验。纳米炭铁是在公司产品纳米炭混悬注射液基础上研究开发的新 一代纳米药物，以Fe2+作为抗癌有效成分，纳米炭作为Fe2+的载体，通过调控铁死亡通路发挥抗癌作 用。截至目前，纳米炭铁二期临床试验进展顺利，已完成部分入组试验。尚无纳米炭铁同类产品上市或 处于在研末期。 （文章来源：每日经济新闻） ...

Core Viewpoint - The 2025 Shanghai International Biopharmaceutical Industry Week, themed "Linking the World, Empowering Industries," aims to foster innovation and collaboration in the biopharmaceutical sector, showcasing Shanghai's supportive ecosystem for drug and medical device development [1] Group 1: Ecosystem and Investment - The investment summit highlighted the importance of a robust innovation ecosystem, with Tsinghua University professor Hong Bo discussing brain-computer interfaces and their potential market impact, supported by significant funding from Shanghai state-owned capital [2] - The collaboration between academia and industry in Shanghai is crucial for the development of cutting-edge technologies, such as brain-computer interfaces, which require a steady supply of talent and resources [2] Group 2: Scientific Advancements - HIF (hypoxia-inducible factor) research is emerging as a critical area in cancer treatment, with Nobel laureate Greg Semenza presenting promising dual inhibitors targeting HIF-1α and HIF-2α, indicating Shanghai's potential as a hub for groundbreaking drug development [3] - Innovative projects from Shanghai universities, such as the development of allogeneic CAR-T cells, are progressing towards commercialization, demonstrating the city's capacity for translating academic research into viable products [4][5] Group 3: Policy Support and Market Access - Shanghai's "New and Excellent Drugs and Medical Devices" policy has accelerated the process for innovative products to enter hospitals, significantly reducing the time required for new drugs to be adopted in clinical settings [6] - As of August this year, 196 products have been included in Shanghai's "New and Excellent Drugs and Medical Devices" directory, reflecting the city's commitment to enhancing its biopharmaceutical innovation capabilities [6]

Core Viewpoint - Sanofi Pharmaceutical (01530) shares have increased by over 4%, currently trading at 31.66 HKD with a transaction volume of 940 million HKD, following the completion of a subscription agreement with Pfizer [1] Group 1: Financial Details - Sanofi Pharmaceutical announced that all conditions for the subscription agreement have been met and completed on August 1, resulting in the issuance of 31.1425 million shares at a subscription price of 25.2055 HKD per share [1] - The net proceeds from this issuance amount to approximately 785 million HKD, with 80% allocated for enhancing the global research and development pipeline for clinical and preclinical projects, and 20% for other general corporate purposes [1] Group 2: Strategic Focus - CITIC Securities released a report indicating that Pfizer is focusing on four major areas: breast cancer, urogenital system cancer, hematological cancer, and thoracic tumors, with plans to launch at least eight blockbuster oncology drugs by 2030 [1] - SSGJ-707, a dual-target antibody for PD-1 and VEGF, is well-aligned with Pfizer's core oncology treatment areas, and the company will prioritize the clinical development of SSGJ-707 in lung cancer, colorectal cancer, and breast cancer to address unmet clinical needs across multiple cancer types [1]